<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312719</article-id>
      <article-id pub-id-type="pmc">4540553</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153708</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Serious stomatitis and esophagitis: a peculiar mucous reaction induced by
pegylated liposomal doxorubicin<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>Han</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Meilan</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Junru</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Ying</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Juan</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <aff id="aff01"><label>1</label>Sun Yat-sen University - Guangzhou, China.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Han Ma and Juan Li, Department of Dermatology,
Department of Hematology, Third Affiliated Hospital and First Affiliated Hospital,
Sun Yat-sen University, No. 600 Tianhe Road, Guangzhou, 510630 Guangdong, China.
E-mail: <email>drmahan@sina.com</email>; <email>drlijuan@sina.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflicts of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>209</fpage>
      <lpage>211</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>5</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Pegylated liposomal doxorubicin is an important antineoplastic agent with activity in
a variety of solid tumors. It has a totally different profile of pharmacokinetics and
toxicity compared with doxorubicin. It rarely causes side-effects like cardiotoxicity
or hair loss, but frequently results in many kinds of mucocutaneous reactions,
including palmar-plantar erythrodysesthesia, diffuse follicular rash, intertrigo-like
eruption, new formation of melanotic macules, stomatitis and radiation recall
dermatitis. We present a rare case of multiple myeloma who immediately developed
serious stomatitis and esophatitis associated with minor palmar-plantar
erythrodysesthesia after a single course of pegylated liposomal doxorubicin.</p>
      </abstract>
      <kwd-group>
        <kwd>Doxorubicin</kwd>
        <kwd>Esophagitis</kwd>
        <kwd>Stomatitis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Pegylated liposomal doxorubicin is an encapsulation form of doxorubicin. It has a
totally different profile of pharmacokinetics and toxicity. Adverse reactions are
predominantly six patterns of mucocutaneous eruptions, including palmar-plantar
erythrodysesthesia (PPE), diffuse follicular rash, intertrigo-like eruption, new
formation of melanotic macules, stomatitis and radiation recall dermatitis.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> We present a rare case of multiple
myeloma (MM) who immediately developed serious stomatitis and esophatitis associated
with minor PPE after a single course of pegylated liposomal doxorubicin.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 69-year-old female presented with lower back pain for five months. Laboratory
examination showed elevated serum IgG (66.1 g/L). Serum immunofixation revealed a
characteristic pattern of monoclonal IgG gammopathy, particularly of &#x3BB; paraprotein.
Magnetic resonance imaging (MRI) suggested minor compression fractures of the
T<sub>12</sub> and L<sub>3</sub> vertebral bodies and a geographic osteolytic lesion
involving almost the whole thoracic, lumbar and sacral vertebrae. Subsequently, positron
emission/ tomography computed tomography (PET/CT) scan showed multiple areas of abnormal
uptake in the T<sub>12</sub> and L<sub>3</sub> vertebral bodies, left sternoclavicular
joint and pubic symphysis. A bone marrow aspirate revealed active myeloid proliferation
and 33% of plasmacytes. The patient was diagnosed with MM and VADM chemotherapy was
delivered as follows: vincristine 0.5 mg d1-4, pegylated liposomal doxorubicin 15 mg
d1-4, dexamethasone 10 mg d1-4 and melphalan 6mg twice a day d1-4.</p>
      <p>On the third day of the chemotherapy course, the patient complained of subxiphoid pain
while swallowing. Two days after the last infusion of chemotherapy drugs, the patient
began to present neutropenic fever, developed multiple painful oral ulcers and showed no
response to many kinds of broad-spectrum antibiotics (<xref ref-type="fig" rid="f01">Figure 1</xref>). One week later, minor PPE with asymptomatic desquamation was
observed. Gastroscopic observation revealed serious, anular, geographic ulcers in the
mid/distal esophagus and chronic stomach inflammation (<xref ref-type="fig" rid="f01">Figures 1</xref> and <xref ref-type="fig" rid="f02">2</xref>). Histopathologic
examination of the esophageal tissue revealed superficial tissue necrosis, formation of
granulation tissue and a lot of lymphocytes, histiocytes and eosinophils infiltrated
into the connective tissue (<xref ref-type="fig" rid="f02">Figure 2</xref>). Two more
weeks later, all the aforementioned symptoms resolved spontaneously without any special
treatments. One month later, the patient received the second course of chemotherapy and
was switched to CTD in consideration of side-effects: cyclophosphamide 1.2 g d1,
thalidomide 200 mg d1-28 and dexamethasone 20 mg d1-4. No similar symptoms came
again.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Multiple painful oral ulcers <bold>(A and B)</bold>. Minor PPE with asymptomatic
desquamation <bold>(C and D)</bold></p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0209-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Gastroscopic observation. Annular, geographic ulcers in the mid <bold>(A)</bold>
and distal <bold>(B)</bold> esophagus. Chronic stomach infl ammation <bold>(C and
D)</bold>. Histopathologic examination of the esophageal tissue.
<bold>(E)</bold> Superficial tissue necrosis, formation of granulation tissue
(hematoxylin-eosin stain, original magnifi cation&#xD7;100). <bold>(F)</bold>
Lymphocytes, histiocytes and eosinophils infiltrated into the connective tissue
(hematoxylin-eosin stain, original magnifi cation&#xD7;400)</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0209-g02"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The pegylated liposomal form of doxorubicin is an important antineoplastic agent with
activity in a variety of solid tumors, such as metastatic breast cancer, aggressive
Non-Hodgkin lymphoma, non-small cell lung cancer, multiple myeloma, gastrointestinal
malignancies, the acquired immunodeficiency syndrome-related Kaposi's sarcoma and
refractory ovarian cancer.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> It rarely
causes side-effects like cardiotoxicity or hair loss, but frequently results in many
kinds of mucocutaneous reactions. One of its major toxic effects is stomatitis, which
was found to be the dose-limiting factor for the maximal single dose and was less
dependent on schedule. Most patients experienced only minor toxic effects and did not
require dose modifications.<sup><xref rid="r01" ref-type="bibr">1</xref></sup>Iqbal S et
al reported 2 of 32 patients with advanced solid tumors treated with pegylated liposomal
doxorubicin and docetaxel who experienced stomatitis, anorexia, esophagitis and
neutropenic fever.<sup><xref rid="r03" ref-type="bibr">3</xref></sup> However, no
details about the severity of the adverse reactions were revealed. Muggia FM et al
reported 1 of 43 patients with persistent or recurrent endometrial carcinoma treated
with pegylated liposomal doxorubicin who experienced grade 4 toxicities , which were-
one episode each of esophagitis, hematuria and vomiting.<sup><xref rid="r04" ref-type="bibr">4</xref></sup> To our knowledge, grade 4 stomatitis and esophagitis
associated with grade 1 PPE induced by pegylated liposomal doxorubicin, just as
presented in this case, is really unusual.</p>
      <p>It is rarely reported that conventional doses of vincristine and melphalan cause
stomatitis or esophagitis. Thus, pegylated liposomal doxorubicin aroused our suspicion.
One week after the last infusion of chemotherapy drugs, evidence was furnished as PPE
occurred. Finally, no similar symptoms came again when the patient received the second
course of chemotherapy (switched from VADM to CTD). All of the above helped us to
confirm the final diagnosis in this case. We propose the replacement of stomatitis by
oral or gastroesophageal mucous reaction as one of the six skin adverse reactions
associated with pegylated liposomal doxorubicin.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Ma H, Chen M, Liu J, Li Y, Li J. Serious
stomatitis and esophagitis: a peculiar mucous reaction induced by pegylated liposomal
doxorubicin. An Bras Dermatol. 2015;90(3 Supl 1):S209-11.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Study conducted at the Third Affiliated Hospital and First Affiliated Hospital, Sun
Yat-sen University, Guangzhou - Guangdong, China.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lotem</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hubert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lyass</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Goldenhersh</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Ingber</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Peretz</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Skin toxic effects of polyethylene glycol-coated liposomal
doxorubicin</article-title>
          <source>Arch Dermatol</source>
          <year>2000</year>
          <volume>136</volume>
          <fpage>1475</fpage>
          <lpage>1480</lpage>
          <pub-id pub-id-type="pmid">11115157</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mangana</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zipser</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Conrad</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Oberholzer</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Cozzio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Knuth</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Skin problems associated with pegylated liposomal doxorubicin-more
than palmoplantar erythrodysesthesia syndrome</article-title>
          <source>Eur J Dermatol</source>
          <year>2008</year>
          <volume>18</volume>
          <fpage>566</fpage>
          <lpage>570</lpage>
          <pub-id pub-id-type="pmid">18693162</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iqbal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tsao-Wei</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Gitlitz</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Groshen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aparicio</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase I clinical trial of pegylated liposomal Doxorubicin and
docetaxel in patients with advanced solid tumors</article-title>
          <source>Am J Clin Oncol</source>
          <year>2011</year>
          <volume>34</volume>
          <fpage>27</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">20142723</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muggia</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Blessing</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Sorosky</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>GC</given-names>
            </name>
          </person-group>
          <article-title>Phase II trial of the pegylated liposomal doxorubicin in previously
treated metastatic endometrial cancer: a Gynecologic Oncology Group
study</article-title>
          <source>J Clin Oncol</source>
          <year>2002</year>
          <volume>20</volume>
          <fpage>2360</fpage>
          <lpage>2364</lpage>
          <pub-id pub-id-type="pmid">11981008</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
